{"id":340383,"date":"2026-11-05T13:06:47","date_gmt":"2026-11-05T07:36:47","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=340383"},"modified":"2026-11-05T13:06:47","modified_gmt":"2026-11-05T07:36:47","slug":"wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\/","title":{"rendered":"3 Wires and Cables Maker, Finished Dosage Generics Maker and Branded Denim Apparel Company Stocks With a Strong Future Roadmap: Polycab India, Strides Pharma Science and Kewal Kiran Clothing"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Polycab India, Strides Pharma Science and Kewal Kiran Clothing: ROE of 15.4% to 24.1% and FY22 to FY26 revenue CAGR of 11.8% to 24.1%. Prices as of 4 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three cable maker, generic drug and denim brand stocks to watch are Polycab India, Strides Pharma Science and Kewal Kiran Clothing. Their return on equity ranges from 15.4% to 24.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.8% to 24.1%. Polycab India leads on both return on equity at 24.1% and revenue growth at 24.1% a year. Prices are based on the 4 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Cable maker, generic drug and denim brand stocks offer a focused view of a sector where demand keeps widening. Polycab India, Strides Pharma Science and Kewal Kiran Clothing cover a wires and cables maker, a finished dosage generics maker and a branded denim apparel company.<\/p>\n<p>This list covers three cable maker, generic drug and denim brand stocks with complete current figures: Polycab India, Strides Pharma Science and Kewal Kiran Clothing. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\/#What_Are_Cable_Maker_Generic_Drug_and_Denim_Brand_Stocks\" title=\"What Are Cable Maker, Generic Drug and Denim Brand Stocks?\">What Are Cable Maker, Generic Drug and Denim Brand Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\/#Cable_Maker_Generic_Drug_and_Denim_Brand_Stocks_at_a_Glance\" title=\"Cable Maker, Generic Drug and Denim Brand Stocks at a Glance\">Cable Maker, Generic Drug and Denim Brand Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\/#Why_Do_Cable_Maker_Generic_Drug_and_Denim_Brand_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Cable Maker, Generic Drug and Denim Brand Stocks Have a Strong Roadmap in India?\">Why Do Cable Maker, Generic Drug and Denim Brand Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\/#Why_Polycab_India_Features_Among_These_Cable_Maker_Generic_Drug_and_Denim_Brand_Stocks\" title=\"Why Polycab India Features Among These Cable Maker, Generic Drug and Denim Brand Stocks\">Why Polycab India Features Among These Cable Maker, Generic Drug and Denim Brand Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\/#Why_Strides_Pharma_Science_Features_Among_These_Cable_Maker_Generic_Drug_and_Denim_Brand_Stocks\" title=\"Why Strides Pharma Science Features Among These Cable Maker, Generic Drug and Denim Brand Stocks\">Why Strides Pharma Science Features Among These Cable Maker, Generic Drug and Denim Brand Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\/#Why_Kewal_Kiran_Clothing_Features_Among_These_Cable_Maker_Generic_Drug_and_Denim_Brand_Stocks\" title=\"Why Kewal Kiran Clothing Features Among These Cable Maker, Generic Drug and Denim Brand Stocks\">Why Kewal Kiran Clothing Features Among These Cable Maker, Generic Drug and Denim Brand Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\/#Polycab_India_vs_Strides_Pharma_Science_vs_Kewal_Kiran_Clothing_on_Key_Financials\" title=\"Polycab India vs Strides Pharma Science vs Kewal Kiran Clothing on Key Financials\">Polycab India vs Strides Pharma Science vs Kewal Kiran Clothing on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\/#Key_Risks_to_Check_Before_Investing_in_Cable_Maker_Generic_Drug_and_Denim_Brand_Stocks\" title=\"Key Risks to Check Before Investing in Cable Maker, Generic Drug and Denim Brand Stocks\">Key Risks to Check Before Investing in Cable Maker, Generic Drug and Denim Brand Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\/#Final_Thoughts_on_Cable_Maker_Generic_Drug_and_Denim_Brand_Stocks\" title=\"Final Thoughts on Cable Maker, Generic Drug and Denim Brand Stocks\">Final Thoughts on Cable Maker, Generic Drug and Denim Brand Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\/#What_are_cable_maker_generic_drug_and_denim_brand_stocks\" title=\"What are cable maker, generic drug and denim brand stocks?\">What are cable maker, generic drug and denim brand stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\/#Which_cable_maker_generic_drug_and_denim_brand_stocks_are_covered_in_this_list\" title=\"Which cable maker, generic drug and denim brand stocks are covered in this list?\">Which cable maker, generic drug and denim brand stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\/#Why_do_cable_maker_generic_drug_and_denim_brand_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do cable maker, generic drug and denim brand stocks have a strong future roadmap in India?\">Why do cable maker, generic drug and denim brand stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\/#How_has_Polycab_India_performed_financially\" title=\"How has Polycab India performed financially?\">How has Polycab India performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\/#How_has_Strides_Pharma_Science_performed_financially\" title=\"How has Strides Pharma Science performed financially?\">How has Strides Pharma Science performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\/#How_has_Kewal_Kiran_Clothing_performed_financially\" title=\"How has Kewal Kiran Clothing performed financially?\">How has Kewal Kiran Clothing performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\/#What_risks_should_investors_check_before_buying_cable_maker_generic_drug_and_denim_brand_stocks\" title=\"What risks should investors check before buying cable maker, generic drug and denim brand stocks?\">What risks should investors check before buying cable maker, generic drug and denim brand stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim-apparel-company-stocks-roadmap-skylark-list\/#Is_this_list_of_cable_maker_generic_drug_and_denim_brand_stocks_investment_advice\" title=\"Is this list of cable maker, generic drug and denim brand stocks investment advice?\">Is this list of cable maker, generic drug and denim brand stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Cable_Maker_Generic_Drug_and_Denim_Brand_Stocks\"><\/span><strong>What Are Cable Maker, Generic Drug and Denim Brand Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Cable maker, generic drug and denim brand stocks are listed companies that make wires, cables and consumer electricals, sell finished dosage generics to the United States and other markets, and own denim and casual wear brands sold through stores and online. Their earnings depend on housing and grid spend, drug approvals and apparel demand.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Cable_Maker_Generic_Drug_and_Denim_Brand_Stocks_at_a_Glance\"><\/span><strong>Cable Maker, Generic Drug and Denim Brand Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/polycab\/polycab-india-ltd-share-price-today\">Polycab India<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,930<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">115,291<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">42.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">24.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.02<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/star\/strides-pharma-science-ltd-share-price-today\">Strides Pharma Science<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,014.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,491<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.57<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/kkcl\/kewal-kiran-clothing-ltd-share-price-today\">Kewal Kiran Clothing<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">434.05<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,588<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.11<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, all three trade at a P\/E below their industry P\/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing cable maker, generic drug and denim brand stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in cable maker, generic drug and denim brand stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Cable_Maker_Generic_Drug_and_Denim_Brand_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Cable Maker, Generic Drug and Denim Brand Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Cable maker, generic drug and denim brand stocks have a strong roadmap in India because strong housing and grid work, wider generic drug demand and rising branded apparel buying keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Cables.<\/strong> New buildings and grids need wiring.<\/li>\n<li><strong>Generic drugs.<\/strong> Regulated markets buy dependable supply.<\/li>\n<li><strong>Denim apparel.<\/strong> Brand-conscious youth buy more.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Polycab_India_Features_Among_These_Cable_Maker_Generic_Drug_and_Denim_Brand_Stocks\"><\/span><strong>Why Polycab India Features Among These Cable Maker, Generic Drug and Denim Brand Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the cable maker, generic drug and denim brand stocks on this list, Polycab India is a leading maker of wires and cables, with a growing range of fast moving electrical goods that includes fans, lighting, switches and switchgear, and a project business in engineering and procurement.<\/p>\n<p>Revenue rose from Rs 12,294 crore in FY22 to Rs 29,120 crore in FY26, a compound annual growth rate of 24.1%. Net profit grew from Rs 845 crore in FY22 to Rs 2,708 crore in FY26, which works out to a compound annual growth rate of 33.8%.<\/p>\n<p>The company has a return on equity of 24.1%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 115,291 crore. The stock trades at a P\/E of 36.0, below the industry P\/E of 42.9.<\/p>\n<p><strong>Roadmap:<\/strong> Spending on housing, power networks and industry is lifting demand for cables, while the company is deepening its presence in consumer electricals through its dealer network. Capacity additions help it serve both retail and project customers.<\/p>\n<p><strong>What to watch:<\/strong> Monitor cable volumes and the growth of its consumer electricals range.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Strides_Pharma_Science_Features_Among_These_Cable_Maker_Generic_Drug_and_Denim_Brand_Stocks\"><\/span><strong>Why Strides Pharma Science Features Among These Cable Maker, Generic Drug and Denim Brand Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the electrical, pharma and apparel shares on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.<\/p>\n<p>The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P\/E of 15.0, below the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.<\/p>\n<p><strong>What to watch:<\/strong> Track new US launches and the pace of price erosion in generic categories.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Kewal_Kiran_Clothing_Features_Among_These_Cable_Maker_Generic_Drug_and_Denim_Brand_Stocks\"><\/span><strong>Why Kewal Kiran Clothing Features Among These Cable Maker, Generic Drug and Denim Brand Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Kewal Kiran Clothing, based in Mumbai, owns the Killer, Easies, Integriti and Lawman Pg3 brands and sells jeanswear and casual apparel through exclusive stores, multi-brand outlets and online channels.<\/p>\n<p>Revenue rose from Rs 625 crore in FY22 to Rs 1,237 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 81.6 crore in FY22 to Rs 152 crore in FY26, which works out to a compound annual growth rate of 16.9%.<\/p>\n<p>In the June 2026 quarter, revenue grew 17.9% year on year to Rs 292 crore, while net profit rose 28.2% to Rs 41.0 crore. The company has a return on equity of 15.4%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 2,588 crore. The stock trades at a P\/E of 16.1, below the industry P\/E of 33.8.<\/p>\n<p><strong>Roadmap:<\/strong> The company is widening its exclusive store network, building its newer brands and adding product categories beyond denim. Control over its own manufacturing helps it respond quickly to fashion trends, and a debt-light balance sheet supports store expansion.<\/p>\n<p><strong>What to watch:<\/strong> Follow same-store sales and the pace at which newer brands scale.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Polycab_India_vs_Strides_Pharma_Science_vs_Kewal_Kiran_Clothing_on_Key_Financials\"><\/span><strong>Polycab India vs Strides Pharma Science vs Kewal Kiran Clothing on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three cable maker, generic drug and denim brand stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Polycab India<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12,294<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">29,120<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">24.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,708<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9.3%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Strides Pharma Science<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,202<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,009<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.8%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">575<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.5%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Kewal Kiran Clothing<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">625<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,237<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.6%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">152<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.3%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Polycab India posts the highest return on equity in this group at 24.1%. Polycab India combines the largest FY26 revenue at Rs 29,120 crore with the fastest revenue growth, a 24.1% compound annual rate. A useful habit with cable maker, generic drug and denim brand stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several wires and fans, finished dosage and jeans stocks instead of one name, which keeps a single result from deciding the outcome.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Cable_Maker_Generic_Drug_and_Denim_Brand_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Cable Maker, Generic Drug and Denim Brand Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these cable maker, generic drug and denim brand stocks, the main points are: Long-term electrical, pharma and apparel shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Input costs.<\/strong> Metal and material prices can move margins.<\/li>\n<li><strong>Consumer spending.<\/strong> Sales follow festivals, incomes and consumer mood.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter cable maker, generic drug and denim brand stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Cable_Maker_Generic_Drug_and_Denim_Brand_Stocks\"><\/span><strong>Final Thoughts on Cable Maker, Generic Drug and Denim Brand Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Cable maker, generic drug and denim brand stocks reward patient research into demand, execution and financial strength. Polycab India, Strides Pharma Science and Kewal Kiran Clothing each have a clear plan to grow. Based on the 4 November 2026 close, Polycab India trades at Rs 7,930, Strides Pharma Science at Rs 1,014.2 and Kewal Kiran Clothing at Rs 434.05. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these cable maker, generic drug and denim brand stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track cable maker, generic drug and denim brand stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_cable_maker_generic_drug_and_denim_brand_stocks\"><\/span><strong>What are cable maker, generic drug and denim brand stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cable maker, generic drug and denim brand stocks are listed companies that make wires, cables and consumer electricals, sell finished dosage generics to the United States and other markets, and own denim and casual wear brands sold through stores and online. Their earnings depend on housing and grid spend, drug approvals and apparel demand. This list looks at three of them, Polycab India, Strides Pharma Science and Kewal Kiran Clothing, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_cable_maker_generic_drug_and_denim_brand_stocks_are_covered_in_this_list\"><\/span><strong>Which cable maker, generic drug and denim brand stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Polycab India, Strides Pharma Science and Kewal Kiran Clothing. Based on the 4 November 2026 close, Polycab India traded at Rs 7,930, Strides Pharma Science at Rs 1,014.2 and Kewal Kiran Clothing at Rs 434.05. Their return on equity ranges from 15.4% to 24.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.8% to 24.1%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_cable_maker_generic_drug_and_denim_brand_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do cable maker, generic drug and denim brand stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cable maker, generic drug and denim brand stocks have a strong roadmap in India because strong housing and grid work, wider generic drug demand and rising branded apparel buying keep widening the market for these companies. The main drivers are as follows. Cables. New buildings and grids need wiring. Generic drugs. Regulated markets buy dependable supply. Denim apparel. Brand-conscious youth buy more. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Polycab_India_performed_financially\"><\/span><strong>How has Polycab India performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 12,294 crore in FY22 to Rs 29,120 crore in FY26, a compound annual growth rate of 24.1%. Net profit grew from Rs 845 crore in FY22 to Rs 2,708 crore in FY26, which works out to a compound annual growth rate of 33.8%. The company has a return on equity of 24.1%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 115,291 crore. The stock trades at a P\/E of 36.0, below the industry P\/E of 42.9. Looking ahead, spending on housing, power networks and industry is lifting demand for cables, while the company is deepening its presence in consumer electricals through its dealer network. Capacity additions help it serve both retail and project customers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Strides_Pharma_Science_performed_financially\"><\/span><strong>How has Strides Pharma Science performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P\/E of 15.0, below the industry P\/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Kewal_Kiran_Clothing_performed_financially\"><\/span><strong>How has Kewal Kiran Clothing performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 625 crore in FY22 to Rs 1,237 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 81.6 crore in FY22 to Rs 152 crore in FY26, which works out to a compound annual growth rate of 16.9%. In the June 2026 quarter, revenue grew 17.9% year on year to Rs 292 crore, while net profit rose 28.2% to Rs 41.0 crore. The company has a return on equity of 15.4%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 2,588 crore. The stock trades at a P\/E of 16.1, below the industry P\/E of 33.8. Looking ahead, the company is widening its exclusive store network, building its newer brands and adding product categories beyond denim. Control over its own manufacturing helps it respond quickly to fashion trends, and a debt-light balance sheet supports store expansion.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_cable_maker_generic_drug_and_denim_brand_stocks\"><\/span><strong>What risks should investors check before buying cable maker, generic drug and denim brand stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying cable maker, generic drug and denim brand stocks. Input costs. Metal and material prices can move margins. Consumer spending. Sales follow festivals, incomes and consumer mood. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_cable_maker_generic_drug_and_denim_brand_stocks_investment_advice\"><\/span><strong>Is this list of cable maker, generic drug and denim brand stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are cable maker, generic drug and denim brand stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Cable maker, generic drug and denim brand stocks are listed companies that make wires, cables and consumer electricals, sell finished dosage generics to the United States and other markets, and own denim and casual wear brands sold through stores and online. Their earnings depend on housing and grid spend, drug approvals and apparel demand. This list looks at three of them, Polycab India, Strides Pharma Science and Kewal Kiran Clothing, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which cable maker, generic drug and denim brand stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Polycab India, Strides Pharma Science and Kewal Kiran Clothing. Based on the 4 November 2026 close, Polycab India traded at Rs 7,930, Strides Pharma Science at Rs 1,014.2 and Kewal Kiran Clothing at Rs 434.05. Their return on equity ranges from 15.4% to 24.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.8% to 24.1%.\"}},{\"@type\":\"Question\",\"name\":\"Why do cable maker, generic drug and denim brand stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Cable maker, generic drug and denim brand stocks have a strong roadmap in India because strong housing and grid work, wider generic drug demand and rising branded apparel buying keep widening the market for these companies. The main drivers are as follows. Cables. New buildings and grids need wiring. Generic drugs. Regulated markets buy dependable supply. Denim apparel. Brand-conscious youth buy more. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Polycab India performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 12,294 crore in FY22 to Rs 29,120 crore in FY26, a compound annual growth rate of 24.1%. Net profit grew from Rs 845 crore in FY22 to Rs 2,708 crore in FY26, which works out to a compound annual growth rate of 33.8%. The company has a return on equity of 24.1%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 115,291 crore. The stock trades at a P\/E of 36.0, below the industry P\/E of 42.9. Looking ahead, spending on housing, power networks and industry is lifting demand for cables, while the company is deepening its presence in consumer electricals through its dealer network. Capacity additions help it serve both retail and project customers.\"}},{\"@type\":\"Question\",\"name\":\"How has Strides Pharma Science performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P\/E of 15.0, below the industry P\/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.\"}},{\"@type\":\"Question\",\"name\":\"How has Kewal Kiran Clothing performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 625 crore in FY22 to Rs 1,237 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 81.6 crore in FY22 to Rs 152 crore in FY26, which works out to a compound annual growth rate of 16.9%. In the June 2026 quarter, revenue grew 17.9% year on year to Rs 292 crore, while net profit rose 28.2% to Rs 41.0 crore. The company has a return on equity of 15.4%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 2,588 crore. The stock trades at a P\/E of 16.1, below the industry P\/E of 33.8. Looking ahead, the company is widening its exclusive store network, building its newer brands and adding product categories beyond denim. Control over its own manufacturing helps it respond quickly to fashion trends, and a debt-light balance sheet supports store expansion.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying cable maker, generic drug and denim brand stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying cable maker, generic drug and denim brand stocks. Input costs. Metal and material prices can move margins. Consumer spending. Sales follow festivals, incomes and consumer mood. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of cable maker, generic drug and denim brand stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cable Maker, Generic Drug and Denim Brand Stocks with a strong future roadmap: Polycab India, Strides Pharma Science and Kewal Kiran Clothing. Compare price, valuation, return on equity and revenue growth as of 4 November 2026.<\/p>\n","protected":false},"author":34,"featured_media":340382,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,12468,18500,20506,20503,10106,20504,877,9049,20505],"class_list":["post-340383","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-cable-maker","tag-electrical","tag-finished-dosage-and-jeans-stocks","tag-generic-drug-and-denim-brand-stocks","tag-kewal-kiran-clothing","tag-pharma-and-apparel-shares","tag-polycab-india","tag-strides-pharma-science","tag-wires-and-fans"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["340382"],"rank_math_title":["Cable, Generic Drug and Denim Brand Stocks"],"rank_math_description":["Compare 3 cable maker, generic drug and denim brand stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 4 Nov 2026."],"rank_math_focus_keyword":["cable maker, generic drug and denim brand stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-wires-and-cables-maker-finished-dosage-generics-maker-and-branded-denim.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340383","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=340383"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340383\/revisions"}],"predecessor-version":[{"id":340384,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340383\/revisions\/340384"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/340382"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=340383"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=340383"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=340383"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}